Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:ertugliflozin
gptkb:sitagliptin |
| gptkbp:approvalYear |
2017
|
| gptkbp:ATCCode |
A10BD23
|
| gptkbp:contraindication |
gptkb:type_1_diabetes_mellitus
gptkb:diabetic_ketoacidosis |
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:drugClass |
SGLT2 inhibitor
DPP-4 inhibitor antidiabetic combination |
| gptkbp:form |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Steglujan
|
| gptkbp:indication |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Pfizer
gptkb:Merck_&_Co. |
| gptkbp:mechanismOfAction |
inhibits SGLT2 and DPP-4 enzymes
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
headache urinary tract infection nasopharyngitis |
| gptkbp:bfsParent |
gptkb:MRK
gptkb:Steglatro |
| gptkbp:bfsLayer |
5
|